Rational design of an arene ruthenium chlorin conjugate for in vivo anticancer activity.
Fiche publication
Date publication
avril 2014
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BARBERI-HEYOB Muriel, Pr BASTOGNE Thierry, Dr FROCHOT Céline
Tous les auteurs :
Pernot M, Barry NPE, Bastogne T, Frochot C, Barberi-Heyob M, Therrien B
Lien Pubmed
Résumé
A tetranuclear p-cymene ruthenium 5,10,15,20-tetra(3-pyridyl) chlorin complex has been prepared and evaluated in vivo as dual photosensitizer and chemotherapeutic agent on mice bearing an ectopic human oral carcinoma xenograft. The in vivo study was planned using a statistical model. Optimisations of the treatment factors showed that the injected dose was critical, while the light-drug interval, fluence and fluence rate had only a modest impact. The ruthenium-chlorin conjugate was found to accumulate preferentially in the endoplasmic reticulum of KB cells. In addition, a mode of action in vivo dominated by a cytotoxic effect of the complex and not a photodynamic efficiency of the photosensitizer was suggested. (C) 2014 Elsevier B. V. All rights reserved.
Référence
Inorg Chim Acta. 2014 Apr 1;414:134-40.